Idiopathic Pulmonary Fibrosis

June 4, 2015November 5, 2015

Model to Predict IPF Mortality Used Successfully in Systemic Sclerosis-Associated Interstitial Lung Disease

Researchers at the University of British Columbia in Canada recently reported that mortality prediction models used in patients with idiopathic pulmonary fibrosis (IPF) can also be employed to assess short-term ... Read more

June 3, 2015November 5, 2015

Pentoxifylline Appears to Prevent Lung Fibrosis in Experimental Chronic Pulmonary Paracoccidioidomycosis

Idiopathic Pulmonary Fibrosis, News

A new study on an experimental model of pulmonary paracoccidioidomycosis induced by the fungus Paracoccidioides brasiliensis (Pb) showed that pentoxifylline (PTX) therapy administered at an “early” stage of granulomatous inflammation ... Read more

June 3, 2015November 5, 2015

ProMetic Confirms Anti-Fibrotic Effect of Experimental IPF Therapy in Human Kidney Cells

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development, recently presented in London at the annual meeting of the European Renal Association ... Read more

June 2, 2015November 5, 2015

FDA approves Pfizer’s RAPAMUNE To Stabilize Lung Function in Lymphangioleiomyomatosis

Idiopathic Pulmonary Fibrosis, News

Pfizer Inc. recently announced that the FDA has approved RAPAMUNE® (sirolimus) as the first treatment option for stabilizing lung function in patients with lymphangioleiomyomatosis (LAM), a rare, progressive disease that ... Read more

June 1, 2015November 5, 2015

Researchers Take Bold Steps Toward Engineering New Lungs For Translplant

Idiopathic Pulmonary Fibrosis, News

A multidisciplinary team of researchers from Arizona State University’s (ASU) Biodesign Institute, have recently released results from a study that may have important implications for the future of the science ... Read more

May 29, 2015November 5, 2015

Aeolus to Present Lung-ARS & IPF Therapy AEOL 10150 at Upcoming Conference

Idiopathic Pulmonary Fibrosis, News

Aeolus Pharmaceuticals, Inc. has been invited to present data on the progress of the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA) at the upcoming LD Micro Invitational Conference. ... Read more

May 28, 2015November 5, 2015

Differences in Collagen Microstructure May Determine Treatment Response in Fibrotic Lung Diseases

Idiopathic Pulmonary Fibrosis, News

In a new study entitled “Second harmonic generation microscopy reveals altered collagen microstructure in usual interstitial pneumonia versus healthy lung,” the authors investigated differences in the structure of human lung tissues ... Read more

May 25, 2015November 5, 2015

RestorGenex Presents Results of Experimental Idiopathic Pulmonary Fibrosis Therapy

Idiopathic Pulmonary Fibrosis, News

RestorGenex, a biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space, recently announced that Nathan Sandbo, M.D. and ... Read more

May 22, 2015November 5, 2015

Research Findings Show That Veracyte’s Molecular Classifier Improves Non-Surgical IPF Diagnosis Using Bronchoscopy Samples

Idiopathic Pulmonary Fibrosis, News

This week at the American Thoracic Society 2015 International Conference in Denver, Veracyte, Inc., a diagnostic company based in San Francisco, presented preliminary data showing that the company’s molecular classifier ... Read more

May 19, 2015November 5, 2015

Boehringer’s Idiopathic Pulmonary Fibrosis Therapy OFEV Shown To Be Safe, Effective in Longer-Term Study

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced new data on OFEV® (nintedanib) that further supports its efficacy, tolerability and safety in patients with idiopathic pulmonary fibrosis (IPF). The results were presented at the American ... Read more